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Background
Because HIV transmission occurs predominantly across
mucosal surfaces, the ideal vaccine strategy to prevent
infection would be to target HIV at mucosal entry sites of
transmission. We investigated a novel vaccine approach,
which aim is to elicit long-term immunity against HIV
infection at the entry site of the virus. This strategy relies
on the expression of viral proteins from epithelial stem
cells at the basal layer of the epithelium and using a pro-
moter that is specific for terminally differentiated
epithelial.
Methods
The involucrin promoter, which is exclusively expressed in
terminally differentiated epithelial cells, was chosen and
used as a tool. We generated a GFP-tagged replication
competent SIVdeltaNef and a GFP-tagged replication defi-
cient SIVdeltaVifdeltaNef constructs under the transcrip-
tional control of the involucrin promoter (pINV). Viral
stocks used to deliver these constructs to basal epithelial
cells were obtained by their co-transfection with a plasmid
encoding for VSV-G envelope proteins used as pseudotyp-
ing envelope protein of significantly broadened host cell
range.
Results
When administered intradermally to mice, we found that
GFP-reporter gene under the transcriptional control of the
involucrin promoter was expressed in the upper layers of
the epidermis. Although transduced cells were very low in
number, high and sustained anti-GFP antibody production
was observed in vivo. After production of high concentra-
tions of infectious viral particles, we demonstrated the
integrity of our constructs (regions encoding for GAG,
POL and GFP) in the VSV-G pseudotyped viral particles
to be used for inoculation in nonhuman primate model
for AIDS.
Conclusion
After integration of pINV-driven constructs, basal layer
cells will divide and differentiate thus triggering SIV
antigens expression as well as both direct and cross
priming. Long-term antigen expression in upper layers
of the epithelium may occur even after multiple cycles
of epithelia renewal, thus eliciting a long-term immunity
against HIV/SIV infection at the site.
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